AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?

AbbVie is scheduled to report first-quarter 2026 earnings on April 29 before the opening bell, with Zacks Consensus Estimates calling for $14.78 billion in sales and $2.69 in EPS. The article is primarily a preview of expected results rather than new operational information, making the tone largely neutral and the likely market impact modest.

Analysis

AbbVie is scheduled to report first-quarter 2026 earnings on April 29 before the opening bell, with Zacks Consensus Estimates calling for $14.78 billion in sales and $2.69 in EPS. The article is primarily a preview of expected results rather than new operational information, making the tone largely neutral and the likely market impact modest.